

## Total Synthesis of Bryostatin 16 Using a Pd-Catalyzed Diyne Coupling as Macrocyclization Method and Synthesis of C20-*epi*-Bryostatin 7 as a Potent Anticancer Agent

Barry M. Trost\* and Guangbin Dong

Department of Chemistry, Stanford University, Stanford, California 94305-5080, United States

Received June 23, 2010; E-mail: bmtrost@stanford.edu

**Abstract:** Asymmetric total synthesis of bryostatin 16 was achieved in 26 steps in the longest linear sequence and in 39 total steps from aldehyde **10**. A Pd-catalyzed alkyne–alkyne coupling was employed for the first time as a macrocyclization method in a natural product synthesis. A route to convert bryostatin 16 to a new family of bryostatin analogues was developed. Toward this end, 20-*epi*-bryostatin 7 was synthesized from a bryostatin 16-like intermediate; the key step involves a Re-catalyzed epoxidation/ring-opening reaction. Preliminary biological studies indicated that this new analogue exhibits nanomolar anti-cancer activity against several cancer cell lines.

### Introduction

Bryostatins 1–20 were first isolated in 1968 by Pettit and co-workers from the marine bryozoan *Bugula neritina* (Figure 1).<sup>1,2</sup> These structurally complex macrolides exhibit a remarkable range of biological activities, including antineoplastic activity,<sup>3</sup> synergistic chemotherapeutic activity,<sup>4</sup> cognition and memory enhancement,<sup>5</sup> recovery of brain damage,<sup>6</sup> etc.

Stimulated by these appealing biological activities, total syntheses of bryostatins and their analogues have been an attractive goal. The structures of the bryostatins constitute significant synthetic challenges, which include a 26-membered lactone fused by three heavily substituted polyhydropyran (PHP) rings, two acid/base-sensitive *exo*-cyclic unsaturated esters, one congested C16–C17 *trans*-olefin, as well as numerous oxygen-

containing functionalities and stereogenic centers. Previously, only three of the 20 bryostatins have been accessed by total synthesis. In 1990, Masamune and co-workers accomplished the synthesis of bryostatin 7.<sup>7</sup> Their strategy involved use of a highly chemoselective macrolactonization to construct the macrocycle and use of Julia olefination<sup>8</sup> to couple the northern fragment and southern fragment. In 1998, another family member, bryostatin 2, was synthesized by Evans et al.<sup>9</sup> A key feature of Evans' synthesis is that they segregated the target into three polyhydropyran-containing subunits with similar complexity, and then assembled them via Julia olefination, sulfone alkylation, and macrolactonization. Notably, Evans' synthesis also constitutes a formal synthesis of bryostatin 1.<sup>10</sup> In 2000, bryostatin 3, a structurally unique family member, was synthesized by Ohmori, Nishiyama, Yamamura, et al.<sup>11</sup> Julia olefination was also employed to form the C16–C17 alkene, and a high-yielding Yamaguchi esterification was used to furnish the 26-membered lactone. Recently, Hale and co-workers reported a concise synthesis of Masamune's southern fragment, which was recognized as a formal total synthesis of bryostatin 7.<sup>12</sup> These elegant syntheses have illustrated the power of organic synthesis for the creation of molecules of extreme complexity; however, their lengths (>40 steps in the longest linear sequence and >70 total steps) have so far restrained them from serving as a practical supply source for this natural product.

- (1) Pettit, G. R.; Day, J. F.; Hartwell, J. L.; Wood, H. B. *Nature* **1970**, *227*, 962.
- (2) Pettit, G. R.; Herald, C. L.; Doubek, D. L.; Herald, D. L.; Arnold, E.; Clardy, J. *J. Am. Chem. Soc.* **1982**, *104*, 6846.
- (3) For some recent reviews, see: (a) Hale, K. J.; Hummerson, M. G.; Manaviar, S.; Frigerio, M. *Nat. Prod. Rep.* **2002**, *19*, 413. (b) Wender, P. A.; Baryza, J. L.; Hilinski, M. K.; Horan, J. C.; Kan, C.; Verma, V. A. *Beyond Natural Products: Synthetic Analogues of Bryostatin 1*. In *Drug Discovery Research: New Frontiers in the Post-Genomic Era*; Huang, Z., Ed.; Wiley-VCH: Hoboken, NJ, 2007; pp 127–162.
- (4) For a review, see: (a) Newman, D. J.; Cragg, G. M. *J. Nat. Prod.* **2004**, *67*, 1216. (b) For ongoing studies, see <http://clinicaltrials.gov/>. (c) Dowlati, A.; Lazarus, H. M.; Hartman, P.; Jacobberger, J. W.; Whitacre, C.; Gerson, S. L.; Ksenich, P.; Cooper, B. W.; Frisa, P. S.; Gottlieb, M.; Murgo, A. J.; Remick, S. C. *Clin. Cancer Res.* **2003**, *9*, 5929.
- (5) (a) Etcheberrigaray, R.; Tan, M.; Dewachter, I.; Kuiperi, C.; Van der Auwera, I.; Wera, S.; Qiao, L.; Bank, B.; Nelson, T. J.; Koziowski, A. P.; Van Leuven, F.; Alkon, D. L. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 11141. (b) Alkon, D. L.; Sun, M.-K.; Nelson, T. J. *Trends Pharmacol. Sci.* **2007**, *28*, 51. (c) Alkon, D. L.; Epstein, H.; Kuzirian, A.; Bennett, M. C.; Nelson, T. J. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 16432. (d) Sun, M.-K.; Alkon, D. L. *Eur. J. Pharmacol.* **2005**, *512*, 43. (e) Hongpaisan, J.; Alkon, D. L. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 19571.
- (6) Sun, M.-K.; Hongpaisan, J.; Nelson, T. J.; Alkon, D. L. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*, 13620.

- (7) Kageyama, M.; Tamura, T.; Nantz, M. H.; Roberts, J. C.; Somfai, P.; Whritenour, D. C.; Masamune, S. *J. Am. Chem. Soc.* **1990**, *112*, 7407.
- (8) (a) Julia, M.; Paris, J. M. *Tetrahedron Lett.* **1973**, 4833. (b) Kocienski, P. J.; Lythgoe, B.; Ruston, S. *J. Chem. Soc., Perkin Trans. 1* **1978**, 829. Review: (c) Kocienski, P. *Phosphorus Sulfur* **1985**, *24*, 97.
- (9) (a) Evans, D. A.; Carter, P. H.; Carreira, E. M.; Prunet, J. A.; Charette, A. B.; Lautens, M. *Angew. Chem., Int. Ed.* **1998**, *37*, 2354. (b) Evans, D. A.; Carter, P. H.; Carreira, E. M.; Charette, A. B.; Prunet, J. A.; Lautens, M. *J. Am. Chem. Soc.* **1999**, *121*, 7540.
- (10) Pettit, G. R.; Sengupta, D.; Herald, C. L.; Sharkey, N. A.; Blumberg, P. M. *Can. J. Chem.* **1991**, *69*, 856.
- (11) Ohmori, K.; Ogawa, Y.; Obitsu, T.; Ishikawa, Y.; Nishiyama, S.; Yamamura, S. *Angew. Chem., Int. Ed.* **2000**, *39*, 2290.
- (12) Manaviar, S.; Frigerio, M.; Bhatia, G. S.; Hummerson, M. G.; Aliev, A. E.; Hale, K. J. *Org. Lett.* **2006**, *8*, 4477.




Figure 1. Bryostatins.

An attractive goal in synthesis is to access multiple targets with a single route and multiple analogues via a common intermediate. This concept particularly bodes well for the bryostatin synthesis as this natural product contains 20 congeners and syntheses of their analogues are equally valuable.<sup>13</sup> Among all the 20 bryostatins, we noticed that the structures of bryostatins 16 (**1**) and 17<sup>14</sup> possess a unique feature (Figure 1): their C-ring contains a relatively reactive dihydropyran (DHP) moiety. By elaboration of this electron-rich and relatively reactive C19–C20 olefin, we envisioned that bryostatin 16 could act as a pivotal parent structure to allow access to almost all the other naturally occurring bryostatins (except bryostatin 3, 19 and 20).<sup>15</sup> For example, oxidation of C19–C20 olefin could lead to bryostatins 1, 2, 4–9, 12, 14, and 15; a formal hydration of this C–C double bond should provide potential access to the C20-deoxy bryostatins (10, 11, 13, 18). Furthermore, bryostatin 16 also offers an ideal forum for us to employ a Pd-catalyzed tandem alkyne–alkyne coupling followed by 6-*endo-dig* cyclization methodology to access the C-ring DHP motif in an efficient and rapid fashion.<sup>16</sup> In addition, simply by variations in this natural product's synthesis, we should be able to obtain new analogues that might not be easily available from other syntheses. In this full article, we provide a detailed account of our completion of the synthesis of bryostatin 16 and demonstrate a proof of principle in a concise synthesis of 20-*epi*-bryostatin 7 as a potent anticancer agent from a bryostatin 16-like intermediate.<sup>17</sup>


## Results and Discussion

**First-Generation Strategy toward the Synthesis of Bryostatin 16.** Given the difficulties of late-stage installation of the C16–C17 olefin,<sup>18</sup> we conceived of a strategy to introduce this sterically hindered alkene at an earlier stage. From a retrosynthetic viewpoint, the 26-membered lactone could be

accessed via either macrolactonization of a *seco*-acid or intramolecular transesterification of a *seco*-methyl ester such as **2**. The C-ring of bryostatin would be synthesized via the Pd-catalyzed diyne coupling between donor alkyne **3** and acceptor alkyne **4** followed by *endo*-cyclization of the secondary alcohol to form the DHP entity. The A-ring could be formed through acid-catalyzed tandem transesterification followed by methyl ketal formation from lactone **5**. The 4-methylene-2,6-*cis*-tetrahydropyran (THP) moiety in **5** provides a perfect opportunity to examine another tandem transformation, the Ru-catalyzed alkene–alkyne coupling/Michael addition methodology (Scheme 1)<sup>19</sup> between two rather complex fragments (**6** and **7**). Ideally, all of the three PHP rings of bryostatin 16 could be accessible via three tandem, catalytic, and atom-economical transformations.

Alkene **6**, one of the key coupling partners, has been previously synthesized in 16 overall steps from commercially available (*R*)-pantolactone (**8**) (Scheme 2).<sup>13f</sup> Although this synthesis is practical, to improve the efficiency our initial goal was to shorten the synthesis of fragment **6**.

Starting from aldehyde **10**, the same aldehyde used in the synthesis of fragment **7**,<sup>20</sup> aldehyde **9** was quickly afforded by asymmetric Brown allylation with (–)- $\beta$ -allyldiisopinocampheylborane [Ipc<sub>2</sub>B(allyl)],<sup>21</sup> followed by PMB protection with PMBBBr/NaH, and oxidative cleavage of the terminal olefin (Scheme 3).<sup>22</sup> As aldehyde **9** is a common intermediate with our previous route, with this modification alkene **6** is now available in 11 steps from aldehyde **10** (eq 1) which, in turn, is commercially available or derived in two steps from 2,2-dimethyl-1,3-propanediol.<sup>19</sup>



With both alkene **6** and alkyne **7** in hand, the Ru-catalyzed tandem alkene–alkyne coupling/Michael addition proceeded to generate *cis*-tetrahydropyran **5** (eq 2). The chemoselectivity was further demonstrated by the high compatibility of a  $\beta,\gamma$ -unsaturated ketone, a six-membered lactone, an unprotected allylic alcohol, a PMB ether, and two different silyl ethers in

(13) For recent examples of bryostatin analogues, see: (a) Keck, G. E.; Li, W.; Kraft, M. B.; Keddi, N.; Lewin, E.; Blumberg, P. M. *Org. Lett.* **2009**, *11*, 2277. (b) Keck, G. E.; Poudel, Y. B.; Welch, D. S.; Kraft, M. B.; Truong, A. P.; Stephens, J. C.; Keddi, N.; Lewin, N. E.; Blumberg, P. M. *Org. Lett.* **2009**, *11*, 593. (c) Wender, P. A.; Horan, J. C.; Verma, V. A. *Org. Lett.* **2008**, *10*, 3331. (d) Wender, P. A.; DeChristopher, B. A.; Schrier, A. J. *J. Am. Chem. Soc.* **2008**, *130*, 6658. (e) Keck, G. E.; Kraft, M. B.; Truong, A. P.; Li, W.; Sanchez, C. C.; Keddi, N.; Lewin, N. E.; Blumberg, P. M. *J. Am. Chem. Soc.* **2008**, *130*, 6660. (f) Trost, B. M.; Yang, H.; Thiel, O. R.; Frontier, A. J.; Brindle, C. S. *J. Am. Chem. Soc.* **2007**, *129*, 2206.

(14) Pettit, G. R.; Gao, F.; Blumberg, P. M.; Herald, C. L.; Coll, J. C.; Kamano, Y.; Lewin, N. E.; Schmidt, J. M.; Chapuis, J.-C. *J. Nat. Prod.* **1996**, *59*, 286.

(15) For biosynthetic approaches, see: (a) Sudek, S.; Lopanik, N. B.; Waggoner, L. E.; Hildebrand, M.; Anderson, C.; Liu, H.; Patel, A.; Sherman, D. H.; Haygood, M. G. *J. Nat. Prod.* **2007**, *70*, 67. (b) Kerr, R. G.; Lawry, J.; Gush, K. A. *Tetrahedron Lett.* **1996**, *37*, 8305.

(16) Trost, B. M.; Frontier, A. J. *J. Am. Chem. Soc.* **2000**, *122*, 11727.

(17) For a preliminary report of a portion of this work, see: (a) Trost, B. M.; Dong, G. *Nature* **2008**, *456*, 485.

(18) For an unsuccessful macrocyclic RCM or a RRCM strategy, see: (a) Ball, M.; Bradshaw, B. J.; Dumeunier, R.; Gregson, T. J.; MacCormick, S.; Omori, H.; Thomas, E. J. *Tetrahedron Lett.* **2006**, *47*, 2223. (b) Refs 7, 9, 11 and 13f.


(19) Trost, B. M.; Yang, H.; Wuitschik, G. *Org. Lett.* **2005**, *7*, 4761.

(20) For a synthesis of compound **7**, see ref 17.


(21) Brown, H. C.; Jadhav, P. K. *J. Am. Chem. Soc.* **1983**, *105*, 2092.

(22) Yu, W.; Mei, Y.; Kang, Y.; Hua, Z.; Jin, Z. *Org. Lett.* **2004**, *6*, 3217.


## Scheme 1. First-Generation Strategy




## Scheme 2. Previous Synthesis of Alkene 6



## Scheme 3. Improved Synthesis of Alkene 6



this reaction. DCM was found to be the optimal solvent, while acetone or a DCM–DMF mixed solvent gave either lower conversion or more decomposition. Notably, only 1.2 equiv of alkene **6** was required in this coupling reaction. Though the yield is moderate, the yield based upon recovered starting material is high (80%, both of the starting materials can be recycled), presumably due to the fact that additional olefin functionality in the alkyne fragment could limit turnover of the Ru catalyst. This result has proved highly reproducible, and the reaction is scalable to several grams.



Advancement of lactone **5** is depicted in Scheme 4. Bromination of the *exo*-cyclic vinyl silane with NBS provided vinyl bromide **12** with retention of the olefin geometry in 98% yield. Subsequently, we attempted a one-pot acid-catalyzed transesterification-methyl ketalization-desilylation transformation. To our delight, treatment of lactone **12** with a catalytic amount of CSA in MeOH cleanly afforded the desired alcohol **13** containing both the A-ring and B-ring substructures in 93–96% yield (on a gram scale). Use of the conditions (PPTS, HC(OMe)<sub>3</sub>,

MeOH, reflux), previously reported for a similar transesterification/ketalization,<sup>13f</sup> gave a messy mixture. We envisaged that the vinyl bromide functionality would serve as a convenient handle in the future for the syntheses of bryostatin analogues via the use of metal-catalyzed coupling reactions. As the natural product contains a conjugated methyl ester at the C30 position, a carbonylation reaction of **13** was next examined. On a smaller scale (less than 100 mg), Pd(PPh<sub>3</sub>)<sub>4</sub> acted as a good carbonylation catalyst, giving up to 78% yield (94% yield brsm); however, on a larger scale, these conditions suffered from poor conversion (less than 50% conversion). After surveying a number of Pd catalysts, this problem was eventually solved by using PdCl<sub>2</sub>(CH<sub>3</sub>CN)<sub>2</sub>–dppf as the catalyst, in which an 83% yield (90% yield brsm) of ester **14** was obtained on a 0.76 g scale.

The conditions for oxidizing primary alcohol **14** to aldehyde **15** were next optimized (Table 1). It is known that the methyl ketal of substrates like **14** is very sensitive to acidic conditions.<sup>23,24</sup> Thus, Ley oxidation (TPAP–NMO),<sup>25</sup> known as a nonacidic oxidation method, was initially employed. Using 0.1 equiv TPAP and 3 equiv NMO in CH<sub>3</sub>CN, the reaction gave full conversion but only 65% yield

(23) Yang, H. Ph.D. thesis, Stanford University, 2006.

(24) Similar observation has also been reported by Evans, see ref 9b.

(25) Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. *Synthesis* **1994**, 639.

Scheme 4. Synthesis of Aldehyde 15




Table 1. Oxidation of Alcohol 14


entry	conditions	yield, % <sup>b</sup>
1	TPAP(0.1 equiv), NMO (3 equiv), 4A M.S., CH <sub>3</sub> CN	65
2	TPAP(0.1 equiv), NMO (2 equiv), 4A M.S., CH <sub>3</sub> CN	67
2	TPAP(0.1 equiv), NMO (2 equiv), 4A M.S., DCM	56–70
3	TPAP(0.08 equiv), NMO (2 equiv), 4A M.S., DCM	74 <sup>a</sup>
4	TPAP(0.1 equiv), NMO (1.5 equiv), 4A M.S., DCM	77 <sup>a</sup>
5	TPAP(0.05 equiv), NMO (1.5 equiv), 4A M.S., DCM	77 <sup>a</sup>
6	DMP(3 equiv), NaHCO <sub>3</sub> (20 equiv), DCM	88 (0.83 g scale)

<sup>a</sup> The reaction did not give full conversion. <sup>b</sup> Isolated yield.

of aldehyde **15** (entry 1). By carefully tuning the reaction conditions, we found that lowering the catalyst loading (entry 3) or the oxidant loading (entry 4) or both (entry 5), gave cleaner reactions and higher yield (up to 77% yield). DCM was also discovered to be a more suitable solvent than CH<sub>3</sub>CN. Subsequently, a more effective oxidation was found; treatment of alcohol **14** with Dess–Martin periodinane (DMP) and excess NaHCO<sub>3</sub>, efficiently afforded aldehyde **15** in 88% yield on a 0.83 g scale.

Advancement of aldehyde **15** to the key coupling partner **3** was achieved in two steps (eq 3). Treatment of **15** with the Ohira–Bestmann reagent nicely provided the corresponding terminal alkyne in quantitative yield. As removal of the TBDPS protecting group at a late stage proved to be problematic,<sup>23</sup> it was removed before the subsequent coupling with the other fragment. Due to its robust nature, the TBDPS deprotection required some experimentation. When 2.5 equiv TBAF (1.0 M in THF) was used, alcohol **3** was isolated in only 60% yield along with a significant amount of retro-aldol,  $\beta$ -hydroxyl elimination, and ester hydrolysis byproducts. Formation of those byproducts was likely caused by the strong basic nature of TBAF as well as the hydroxide present in commercial TBAF. To minimize those undesired reaction pathways, we envisioned that it would be helpful to add a buffer and to control the reaction pH and concentration. Indeed, treatment of the TBDPS ether with less TBAF (1.1 equiv) and buffered with 20 mol % HOAc at a lower concentration, led to the chemoselective

cleavage of the TBDPS group and provided alcohol **3** in 90% yield (96% brsm).



With alkyne **3** in hand, we continued to examine the plan of uniting the two fragments together via diyne coupling and then closing the macrocycle via lactonization. Pd-catalyzed alkyne–alkyne coupling between fragments **3** and **4** proceeded very well, giving enyne **16** in 80% yield (Scheme 5). A gold-catalyzed 6-*endo-dig* cyclization was subsequently employed to build the C-ring subunit.<sup>26</sup> A 4:1 mixture of DCM–CH<sub>3</sub>CN was found to be the optimal choice of solvent, and dihydropyran **17** was isolated as the major product in 65% yield.


The acetonide protecting group was efficiently removed with a catalytic amount of CSA in MeOH. However, under those conditions, the external C21–C34 olefin isomerized, yielding a ~1:1 mixture of olefin geometric isomers (**18**). Transesterification of *seco*-ester **18** to form the macrolactone **19** was briefly explored. Treatment of **18** with 10 mol % Otera's catalyst<sup>27</sup> in refluxing toluene or hexanes, however, did not provide any macrocycle, even when using 5 Å molecular sieves to remove MeOH. Attempts to hydrolyze the C1 methyl ester of **18** followed by macrolactonization was not fruitful either. The major difficulties were due to the fragile nature of the external C21–C34 olefin leading to the existence of both the starting materials and the potential products as isomeric mixtures which complicated product identification and NMR spectral interpretation. Although this first-generation plan still represents a valid route, given those late-stage difficulties, we resorted to a new strategy.

**Second-Generation Strategy toward the Synthesis of Bryostatin 16.** Given the severe acid sensitivity of the C-ring, instead of carrying it through, we conceived of a strategy for constructing the C-ring of bryostatin 16 at the very end of the synthesis. The benefits of this strategy also include flexible late-stage variations for access to other bryostatins or analogues, as well as minimization of functional group transformations and

(26) For a related model study, see: (a) Dong, G. Ph.D. thesis, Stanford University, 2009.

(27) Otera, J.; Danoh, N.; Nozaki, H. *J. Org. Chem.* **1991**, *56*, 5307.


Scheme 5. End Game of the First-Generation Strategy



protecting group usage. As early as in 1989, we have demonstrated the principle of using Pd-catalyzed  $\alpha,\omega$ -diyne cycloisomerization to form macrocycles.<sup>28</sup> Use of this method in natural product synthesis, however, has not been previously established. While all the previous bryostatin total syntheses have relied on assembling the macrocycle by a demanding Julia olefination followed by a lactonization, we foresaw that we could employ the Pd-catalyzed alkyne–alkyne coupling as a novel macrocyclization method followed by a metal-catalyzed 6-*endo-dig* cyclization to construct both the macrolactone and the C-ring of bryostatin 16 simultaneously (Scheme 6). Esterification between fragments **22** and **23** would provide the requisite diyne precursor. Acid **22** and alcohol **23** would be synthesized respectively from intermediates **3** and **4** from our first route.

Starting from the  $\beta$ -hydroxy methyl ester **3**, the challenge was to hydrolyze the C1 methyl ester chemoselectively in the presence of the C31 methyl ester. We found that heating **3** with trimethyltin hydroxide in DCE<sup>29</sup> provided the desired C1 acid (**24**) in 84% yield (Scheme 7). The desired chemoselectivity was attributed to two factors: first, the conjugated esters are generally less reactive toward hydrolysis than the nonconjugated ones due to the more delocalized  $\pi$ -systems; second, the Lewis acidity of trimethyltin hydroxide allows the adjacent  $\beta$ -hydroxy group to act as a directing group in this saponification reaction. Due to the acid-sensitivity of the methyl ketal functionality, acid

Scheme 6. Synthetic Plan of the Second-Generation Strategy




**24** had to be handled with sufficient care.<sup>30</sup> Subsequent TES protection of the secondary alcohol completed the synthesis of acid fragment **22**.

(28) Trost, B. M.; Matsubara, S.; Carings, J. J. *J. Am. Chem. Soc.* **1989**, *111*, 8745.


(29) Nicolaou, K. C.; Estrada, A. A.; Zak, M.; Lee, S. H.; Safina, B. S. *Angew. Chem., Int. Ed.* **2005**, *44*, 1378.

(30) For example, either extended exposure of **24** to silica gel or storage in neat form led to the loss of the methyl ketal. It was also found that the most desirable way to store acid **24** was to freeze it as a benzene solution.


Scheme 7. Synthesis of Acid Fragment 22



Scheme 8. Esterification between Acid 22 and Alcohol 23



Alcohol fragment **23** was synthesized in three straightforward steps from acetonide intermediate **4**.<sup>31</sup> Cu(OTf)<sub>2</sub>-catalyzed PMB protection of the secondary alcohol,<sup>32</sup> acid-mediated hydrolysis of the acetonide moiety to provide the vicinal diol, and selective TBS-ether protection of the less hindered alcohol gave the alcohol fragment **23** (eq 4). A somewhat diminished yield was observed on a 0.4 g scale in contrast to a 66% yield over three steps on a 3.7 mg scale, which is caused by incomplete conversion of the acetonide hydrolysis on a large scale. As a higher yield can be obtained, this step will be validated by future optimization studies.



Esterification between acid **22** and alcohol **23** was studied under several conditions (Scheme 8). Use of anhydride **27** as the coupling reagent has recently been developed by Shiina,<sup>33</sup> which has been demonstrated as a mild and efficient esterification method. Indeed, use of Shiina's method provided the desired ester (**26**), albeit only in 15–19% yield. Under the reaction conditions, acid **22** was partially decomposed to its desilylated precursor **24**. This reaction also suffered from reproducibility issues on larger scale. Switching to the more

traditional Yamaguchi method,<sup>34</sup> led to satisfactory and consistent results, and ester **26** was isolated in 70–92% yield.

Removal of both PMB protecting groups in one step from **26** proved to be nontrivial (Scheme 9). Treatment of ester **26** with excess DDQ under buffered conditions gave a mixture containing mono-deprotection product **28**, diol **21** and lactol **29**. One interesting observation was that cleavage of the C7 PMB ether was much faster than the one at the C23 position. However, this reaction did not afford complete conversion to diol **21** without generating byproduct **29**. Addition of 2,2-dimethoxypropane has been attempted to prevent the undesirable ketal hydrolysis, but this did not help. After fine-tuning of reaction concentration and the DDQ stoichiometry, we settled on quenching the reaction at a point, which provided 52% yield of mono-deprotection product **28** and 46% yield of double-deprotection product **21** with minimum formation of byproduct **29**. The mono-PMB ether **28** can be recycled and resubjected to the DDQ deprotection conditions to provide more diol **21** in an overall yield of around 72% from ester **26**.

With diyne **21** in hand, the stage was now set for the macrocyclization (eq a). To our delight, the desired macrocycle **30** was provided in 22% yield (44% brsm) when a solution of diyne **21** in benzene was slowly added via syringe pump to the catalyst solution that contains 12 mol % Pd(OAc)<sub>2</sub> and 15 mol % tri(2,6-dimethoxyphenyl)-phosphine (TDMPP) (Table 2, entry 1). Note that a slightly higher ligand/Pd ratio (1.25:1) was used here, since a 1:1 ratio proved less efficient. Solvent effects were next examined. Use of toluene as the solvent proved to be most effective, providing up to 56% yield of macrocycle **30** (entry 3). In contrast, use of THF as the solvent gave a sluggish reaction and only 23% yield was obtained after 5 days (entry 2). Like other macrocyclizations, low concentration (0.002M) proved to be critical; otherwise, formation of the dimeric byproducts

(31) For the synthesis of compound **4**, see ref 13f.

(32) Rai, A. N.; Basu, A. *Tetrahedron Lett.* **2003**, *44*, 2267.

(33) (a) Shiina, I.; Kubota, M.; Oshiumi, H.; Hashizume, M. *J. Org. Chem.* **2004**, *69*, 1822. (b) Shiina, I.; Kubota, M.; Ibuka, R. *Tetrahedron Lett.* **2002**, *43*, 7535. (c) Shiina, I.; Ibuka, R.; Kubota, M. *Chem. Lett.* **2002**, 286.

(34) Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. *Bull. Chem. Soc. Jpn.* **1979**, *52*, 1989.

## Scheme 9. PMB Deprotection





Table 2. Macrocyclization via Alkyne–Alkyne Coupling



entry	solvent	yield, %
1	benzene	22 (44% brsm)
2	THF	23 (5 d)
3 <sup>a</sup>	toluene	56
4 <sup>b</sup>	toluene	36 (57% brsm)

<sup>a</sup> On 3.2 mg scale. <sup>b</sup> On 45 mg scale.

could be observed. This macrocyclization was also performed on a 45-mg scale, but the conversion was lower than the smaller scale reaction (entry 4). To the best of our knowledge, this represents the first example of using a Pd-catalyzed alkyne–alkyne coupling as a macrocyclization method for complex natural product synthesis, which illustrates a new avenue of using C–C bond formation to construct a macrocycle.

Mechanistically,<sup>35</sup> the Pd catalyst chemoselectively inserts into the C–H bond of the terminal alkyne and then eliminates one molecule of acetic acid. Subsequent coordination with the disubstituted alkyne then sets the stage for the chemo- and regioselective intramolecular migratory insertion. The resulting vinylpalladium motif is next protonated by the acetic acid to regenerate the Pd(OAc)<sub>2</sub>–TDMPP catalyst (Scheme 10).

The remaining challenge was to conduct a 6-*endo-dig* cyclization to form the C-ring of bryostatin. This cyclization has to proceed within the macrocycle, and the conformational


bias of the macrocycle may interfere with the desired process. To our delight, use of the cationic gold catalyst gave satisfactory results (Scheme 11). When 20 mol % catalyst was employed, the THP product (**34**) was isolated in 56–73% yield. Notably, likely due to the Lewis acidity of the catalyst, the methyl ketal moiety was hydrolyzed under the cyclization conditions. Subsequent pivalation of the hindered secondary alcohol under rather forcing conditions (Piv<sub>2</sub>O 50 equiv, DMAP 80 equiv, 50 °C)<sup>36</sup> did afford the pivalate ester (**35**) in 62% yield. Other acylation methods, such as use of pivaloyl chloride/Py/DMAP, proved to be less efficient.

The following global deprotection turned out to be nontrivial. Treatment of pivalate ester **35** with HF-pyridine or aqueous HF provided a four-component mixture, which could be further separated into two mixtures: one containing bryostatin 16 (**36**) and one containing bryostatin 17 (**37**) (eq 6). The ratio between mixtures **36** and **37** was roughly 1.5 to 1, determined via <sup>1</sup>H NMR spectroscopy. Bryostatin 17 was likely formed via the acid-catalyzed isomerization of the C21–C34 olefin, but what


(35) For a mechanistic discussion and a full paper, see: (a) Trost, B. M.; Sorum, M. T.; Chan, C.; Ruehter, G. *J. Am. Chem. Soc.* **1997**, *119*, 698.

(36) For a similar pivalation, see ref 10.


Scheme 10. Plausible Mechanism for the Pd-Catalyzed Macrocyclization



Scheme 11. Synthesis of THP 35




were the other two compounds isolated with bryostatin 16 and 17?



We hypothesized that these two mysterious compounds could be the C9 hemiketal diastereomers of the natural products. Although the hemiketal isomer of the THP A-ring drawn in the natural product could be the thermodynamically most stable one if secluded by itself, our previous bryostatin analogue synthesis<sup>13f</sup> indicated

that this may not be true when the THP was fused in a macrocycle and there is a possibility to form both hemiketal isomers. In addition, when the A-ring conformation of the **36/37** mixtures was locked by forming the methyl ketals, the formed products contained only two compounds instead of four (eq 7), which serves as another evidence for our hypothesis, that the two unknown compounds are the C9 epimers of bryostatins 16 and 17.









Figure 2

Given the extreme acid-sensitivity of this natural product, we switched to basic desilylation conditions. Fortunately, treatment of **35** with 5 equiv of TBAF and direct purification by reverse phase HPLC<sup>37</sup> successfully provided bryostatin 16 (eq 8), which was spectroscopically identical to the literature (reported optical rotation  $[\alpha]_D + 84$ ,  $c$  0.43, MeOH; found  $[\alpha]_D + 81$ ,  $c$  0.04, MeOH).<sup>14</sup>



**Total Syntheses of 20-*epi*-Bryostatin 7.** With completion of the total synthesis of bryostatin 16, we decided to address the question of how to convert bryostatin 16 or a bryostatin 16-like compound to other structurally related bryostatins or their analogues (Figure 2).


As illustrated in Scheme 12, during our bryostatin 16 synthesis, the yields for the last several steps were only moderate; and for certain steps, such as DDQ deprotection and macrocyclization, conversion was an issue. To permit enough materials to advance those intermediates, the initial goal was to improve or modify these challenging steps.

As we observed earlier, the PMB group on the C7 alcohol was cleaved faster than the one on the C23 alcohol. By carefully controlling the DDQ stoichiometry (2 equiv) and the reaction temperature (0 °C), the C7 PMB group was chemoselectively removed, providing alcohol **28** in 77% yield (Scheme 13). Subsequent acylation of the secondary C7 alcohol with acetic anhydride and pyridine afforded the corresponding ester in 91% yield. Due to the electron-withdrawing nature of the OAc group, the C9 ketal of the resultant ester became somewhat stabilized and thus less sensitive to acid than its precursor **28**. Consequently, treatment with excess DDQ (10 equiv) at room temperature cleanly led to the second PMB-cleaved product (**39**) in 90% yield.

Macrocyclization with diyne precursor **39** under the conditions developed earlier was effective; however, the yield for macrocycle **40** was only moderate: 41% (71% brsm), and the reaction was slow (3 days). Having surveyed several factors for this Pd-catalyzed alkyne–alkyne coupling, we eventually found that addition of a mild proton source, like an alcohol, was beneficial. As precursor **39** has a methyl acetal moiety,

methanol was used as the additive. With this variation, the yield for this macrocyclization was increased to 65% (72% brsm), and the reaction rate was also enhanced (40 h). The exact reason why an alcohol additive improved both the reaction yield and rate is unclear. We conjecture that a proton source might facilitate protonation of the vinyl palladium intermediate generated in the catalytic cycle (see Scheme 10), which eventually increases the turnover efficiency of the catalyst. The conditions for the 6-*endo-dig* cyclization were next optimized. When macrocycle **40** was subjected to the conditions developed earlier [AuCl(PPh<sub>3</sub>) (20 mol %), AgSbF<sub>6</sub> (20 mol %), NaHCO<sub>3</sub>, DCM/CH<sub>3</sub>CN, 0 °C to rt], in contrast to the reaction of **30**, a complex mixture, containing the desired product (**41**), the product with methyl-ketal hydrolyzed, the starting material with methyl-ketal hydrolyzed was observed. Switching to a platinum catalyst<sup>38</sup> [(PtCl<sub>2</sub>(CH<sub>2</sub>=CH<sub>2</sub>)<sub>2</sub> (20 mol %), NaHCO<sub>3</sub>, DCM or ether, rt] did save the methyl ketal, however, the C21–C34 olefin was isomerized under those reaction conditions. Finally, the problem was solved by adding 2,2-dimethoxypropane to the Au-catalyzed cyclization reaction. To our delight, under the modified conditions, dihydropyran **41** was obtained in 80–83% yield with the methyl ketal remaining intact. During this reaction, 2,2-dimethoxypropane was believed to act as both an acid scavenger and a methyl ketal repairer.

With a scalable route to access the bryostatin 16 intermediate (**41**), efforts were next taken to explore the conditions for the chemoselective and diastereoselective oxidation of the C19–C20 olefin in the presence of three other olefins. An asymmetric dihydroxylation reaction seemed to be the most straightforward method to install two oxygen functionalities stereoselectively on both of the C19 and C20 carbons. Under the Sharpless' asymmetric dihydroxylation (SAD) conditions,<sup>39</sup> to our surprise, the oxidation occurred almost exclusively at the C13–C30 olefin, the olefin that was supposed to be least reactive toward oxidation due to its electron-deficient nature (eq 9). As a result, diol **43** was isolated as the major product in 70% yield; while the more electron-rich C19–20 alkene remains intact. The structure of diol **43** has been carefully confirmed by <sup>1</sup>H NMR, IR, gCOSY, gHSQC, gHMBC, ROSEY, and HRMS. The stereochemistry of the formed diols was tentatively assigned according to the Sharpless model.<sup>39</sup> This unusual chemoselectivity could be explained plausibly by the fact that SAD reaction is more sensitive to steric factors than electronic ones due to the bulkiness of the chiral Os catalyst.




Epoxidation is known to be more sensitive to electronic effects compared to steric effects, thereby a strategy of epoxi-

(37) Isomerization occurred even when trying to purify bryostatin 16 via prep-TLC.


(38) Liu, B.; De Brabander, J. K. *Org. Lett.* **2006**, *8*, 4907.

(39) For a review, see: Kolb, H. C.; Van Nieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* **1994**, *94*, 2483.

Scheme 12. Some Challenging Steps in the Bryostatin 16 Synthesis



Scheme 13. Synthesis of Key Intermediate 41



datation followed by ring-opening with an alcohol was next pursued (eq 14). Although trifluoroperacetic acid (TFPAA) was used to oxidize a less complicated substrate containing a similar C-ring motif,<sup>13f</sup> reaction of **41** under the same conditions only resulted in decomposition of the starting material (Table 3, entry 1). Payne oxidation,<sup>40</sup> with use of either CH<sub>3</sub>CN or CCl<sub>3</sub>CN as the oxidant precursor, failed to provide any identifiable products (entries 2 and 3). On the other hand, a Re-catalyzed epoxidation, using methyl rhenium trioxide (MTO) as the catalyst and urea–hydrogen peroxide (UHP) as the oxidant was promising.<sup>41</sup> Under these conditions, the epoxidation/ring-opening product (**44**) was isolated in around 10% yield, along with some TES

cleavage products (entry 4). Although the yield was low, we were encouraged about the chemoselectivity.


We assumed that TES cleavage was caused by the acid generated during the reaction, thus buffering of the reaction with a base should minimize the undesirable desilylation. Moreover, it is also known that Lewis base can act as a ligand to accelerate the Re-catalyzed epoxidation reaction.<sup>42</sup> Indeed, when *N*-methylimidazole (50 mol %) was added, the reaction proceed with full conversion in two hours at 0 °C. Surprisingly, epoxide **45** turned out to be very stable under those reaction conditions, and it could be isolated via aqueous workup (Scheme 14).<sup>43</sup> Epoxide **45** was subsequently ring-opened with MeOH, either by addition of ZnCl<sub>2</sub> solution to the reaction mixture in a one-pot fashion or treatment of the crude epoxide with dilute HOAc in MeOH, providing C20 alcohol **44** in 48% or 64% yield respectively. It is not totally unexpected that the stereochemistry

(40) (a) Payne, G. B.; Deming, P. H.; Williams, P. H. *J. Org. Chem.* **1961**, *26*, 659. (b) Arias, L. A.; Adkins, S.; Nagel, C. J.; Bach, R. D. *J. Org. Chem.* **1983**, *48*, 888.



(41) For a review, see: Kuhn, F. E.; Santos, A. M.; Herrmann, W. A. *Dalton Trans.* **2005**, 2483. Also, see: (a) Herrmann, W. A.; Fischer, R. W.; Marz, D. W. *Angew. Chem., Int. Ed.* **1991**, *30*, 1638. (b) Boehlow, T. R.; Spilling, C. D. *Tetrahedron Lett.* **1996**, *37*, 2717. (c) Soldaini, G.; Cardona, F.; Goti, A. *Tetrahedron Lett.* **2003**, *44*, 5589.

(42) Rudolph, J.; Reddy, K. L.; Chiang, J. P.; Sharpless, K. B. *J. Am. Chem. Soc.* **1997**, *119*, 6189.

(43) Epoxide **45** decomposed on silica gel.

**Table 3.** An Epoxidation/Ring-Opening Strategy

entry	conditions	results
1	TFPAA, CH <sub>3</sub> CN, Na <sub>2</sub> HPO <sub>4</sub> , DCM/MeOH 0 °C to rt	decomposition of <b>41</b>
2	CCl <sub>3</sub> CN, UHP, Na <sub>2</sub> HPO <sub>4</sub> , DCM/MeOH 0 °C to rt	complete decomposition
3	CH <sub>3</sub> CN, UHP, KHCO <sub>3</sub> , MeOH rt	complex mixture
4	MTO (10 mol %), UHP (2 equiv), MeOH, 0 °C	<b>44</b> (ca. 10%) + TES cleavage products

**Scheme 14.** Synthesis of Alcohol **44****Scheme 15.** End Game of the Synthesis of 20-*epi*-Bryostatin 7 (**47**)

of the C20 alcohol in **44** was opposite to the one in the natural bryostatin,<sup>44</sup> as the Re catalyst likely attacks at the less hindered face of the C-ring at the epoxidation stage. However, *it represented the feasibility to function the C19–C20 olefin chemoselectively in a bryostatin-16 like compound!*

**Synthesis of 20-*epi*-Bryostatin 7.** We envisaged that the unnatural C20-*epimer* of bryostatins, could serve as an attractive new family of bryostatin analogues for two reasons: first, they might retain the biological activities that are comparable or complementary to those of the natural products due to their closely related structures; second, study of these analogues could contribute to our understanding of the structure–activity relationships (SAR) of bryostatins, especially about the role of the C-ring unit generally and the C20 stereocenter specifically.

Consequently, we explored the synthesis of the analogue 20-*epi*-bryostatin 7. Acylation of the C20 alcohol with acetic anhydride, followed by global deprotection with aqueous HF,

afforded 20-*epi*-bryostatin 7 (**47**) in 63% yield over two steps (Scheme 15). The structure of **47** was confirmed by <sup>1</sup>H, gCOSY, gHSQC, gHMBC, IR and HRMS.<sup>45</sup> Note that we are able to install the C7 and C20 ester groups in **47** at different stages, thus this route also represents a valid access to other bryostatin analogues.

20-*epi*-Bryostatin 7 was next tested against several cancer cell lines in a biological assay. Initial biological studies showed that this bryostatin analogue possessed *nanomolar* potency against DOHH2 (a lymphoma cancer cell line), Granta 519 (a lymphoma cancer cell line), and Jurkat (a T-lymphocyte cancer cell line) (Table 4). These biological studies indicate that this new bryostatin analogue could be a potential drug lead for anti-cancer chemotherapy.

## Conclusion

In summary, we have developed a unique and highly concise strategy (26 steps in the longest linear sequence, 39 total steps

(44) A very small ratio of the desired diastereomer was observed, and the dr was about 7:1 favoring the undesired one.


(45) The stereochemistry of the C19 hemi-ketal was tentatively assigned as the same one in the natural product.

**Table 4.** Anticancer Activity of 20-*epi*-Bryostatin 7 (**47**)<sup>a</sup>


cell lines	DOHH2	Granta 519	Jurkat
IC <sub>50</sub> (nM)	22.5	17.6	44.7

<sup>a</sup> DOHH2, a lymphoma cancer cell line; Granta 519, a lymphoma cancer cell line; Jurkat, a T-lymphocyte cancer cell line.

from aldehyde **10**, eq 11) for the asymmetric total synthesis of bryostatin **16**. A Pd-catalyzed alkyne–alkyne coupling was employed for the first-time as a macrocyclization method in natural product synthesis. The efficiency of our synthesis can also be attributed to a tandem Ru-catalyzed alkene–alkyne coupling/Michael addition to form the B-ring, an acid-catalyzed one-pot cascade to form the A-ring, a directed chemoselective ester hydrolysis, and a palladium/gold-catalyzed cascade to form the C-ring of bryostatin **16**. These atom-economical and/or chemoselective approaches not only are useful in bryostatin syntheses, but should also be indicative for the synthesis of numerous other polyacetate–polypropionate-derived natural products.



In addition, we demonstrated the feasibility to functionalize the C-ring of bryostatin **16** by a highly chemo- and stereoselective Re-catalyzed epoxidation/ring-opening reaction. By accomplishing a concise synthesis of a potent anti-cancer agent 20-*epi*-bryostatin **7**, we also proved the principle for the first time that novel bryostatin analogues can be derived from a bryostatin **16**-like intermediate (eq 12). Extension of this strategy in the synthesis of various other natural bryostatins and their analogues, and performance of more systematic biological studies are currently being undertaken.



## Experimental Section

**Compound 5.** CpRu(CH<sub>3</sub>CN)<sub>3</sub>PF<sub>6</sub> (4.0 mg, 0.0092 mmol) was added to a solution of compound **6** (50 mg, 0.080 mmol) and compound **7** (24.5 mg, 0.069 mmol) in DCM (0.4 mL) at 0 °C. The resulting yellow solution was stirred at rt for 12 h. Compound **5** was purified directly via silica gel flash column chromatography (10%, then 15% ethyl acetate/petroleum ether) to give a colorless foam (23.1 mg, 34%; 80% brsm, 45.6 mg **6** + **7** can be recovered).

At a larger scale, compound **6** (969 mg, 1.59 mmol) and compound **7** (471 mg, 1.33 mmol) with CpRu(CH<sub>3</sub>CN)<sub>3</sub>PF<sub>6</sub> (86 mg, 0.199 mmol) in DCM (3 mL), according to the same procedure, gave compound **5** (0.45 g, 35%, 0.19 g, **7** was recovered). *R*<sub>f</sub>: 0.3 (ethyl acetate:petroleum ether, 1:9 v/v); [α]<sub>D</sub><sup>20</sup> (deg cm<sup>3</sup> g<sup>-1</sup> dm<sup>-1</sup>):

−21.1 (*c* 1.27 g cm<sup>-3</sup> in DCM); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 7.63–7.59 (m, 4H), 7.47–7.44 (m, 2H), 7.43–7.37 (m, 4H), 7.13 (d, *J* = 8.5 Hz, 2H), 6.76 (d, *J* = 8.5 Hz, 2H), 5.63 (dd, *J* = 0.5, 16 Hz, 1H), 5.40 (dd, *J* = 7.0, 16 Hz, 1H), 5.26 (s, 1H), 4.55 (d, *J* = 11 Hz, 1H), 4.34 (d, *J* = 11 Hz, 1H), 4.03–3.98 (m, 2H), 3.88–3.80 (m, 2H), 3.73 (m, 1H), 3.73 (s, 3H), 3.25 (s, 2H), 3.00 (dd, *J* = 5.5, 17 Hz, 1H), 2.53 (dd, *J* = 7.0, 18 Hz, 1H), 2.47–2.38 (m, 3H), 2.23 (br d, *J* = 13 Hz, 1H), 1.97 (br dd, *J* = 12, 24 Hz, 2H), 1.90 (ddd, *J* = 2.5, 5.5, 14 Hz, 1H), 1.58–1.55 (m, 2H), 1.48 (dd, *J* = 1.5, 10.5, Hz, 1H), 1.18 (s, 3H), 1.08 (s, 3H), 1.03 (s, 9H), 0.93 (s, 3H), 0.92 (s, 3H), 0.88 (s, 9H), 0.09 (s, 9H), 0.00 (s, 6H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) δ 212.3, 170.4, 159.2, 152.9, 139.2, 135.73, 135.69, 133.4, 133.2, 130.7, 130.12, 130.06, 129.6, 128.0, 127.9, 127.7, 123.7, 113.8, 79.4, 79.3, 75.1, 74.6, 73.2, 71.8, 65.2, 55.3, 52.6, 45.3, 45.2, 40.6, 39.7, 38.9, 38.1, 37.9, 30.4, 26.9, 26.0, 24.0, 23.7, 20.9, 20.8, 19.1, 18.3, 0.4, −5.4; IR (film): 2956, 2858, 1744, 1702, 1612, 1514, 1249, 1094, 838 cm<sup>-1</sup>; HRMS (C<sub>57</sub>H<sub>86</sub>O<sub>8</sub>Si<sub>3</sub>): calcd 1005.5528 (*M* + Na<sup>+</sup>), found 1005.5520.

**Compound 13.** CSA (18 mg, 0.080 mmol) was added to a solution of compound **12** (0.88 g, 0.89 mmol) in MeOH (dry, 18 mL) at 0 °C. The resulting solution was stirred at rt for 12 h, before it was poured into saturated aqueous NaHCO<sub>3</sub>. The mixture was extracted with ethyl acetate three times and the combined organic fractions were dried over Na<sub>2</sub>SO<sub>4</sub>. Compound **13** was purified via silica gel flash column chromatography (15%, then 30% ethyl acetate/petroleum ether) to give a colorless oil (0.76 g, 93%). *R*<sub>f</sub>: 0.2 (ethyl acetate:petroleum ether, 1:4 v/v); [α]<sub>D</sub><sup>20</sup> (deg cm<sup>3</sup> g<sup>-1</sup> dm<sup>-1</sup>): +27.5 (*c* 0.85 g cm<sup>-3</sup> in DCM); <sup>1</sup>H NMR (C<sub>6</sub>D<sub>6</sub>, 400 MHz) δ 7.84–7.80 (m, 4H), 7.26–7.21 (m, 6H), 6.80 (d, *J* = 8.8 Hz, 2H), 5.98 (s, 1H), 5.71 (dd, *J* = 1.2, 16 Hz, 1H), 5.52 (dd, *J* = 5.2, 16 Hz, 1H), 4.58 (m, 1H), 4.38 (d, *J* = 11.2, 1H), 4.18 (d, *J* = 11.2 Hz, 1H), 3.71–3.64 (m, 2H), 3.57 (m, 1H), 3.45 (m, 1H), 3.38 (s, 3H), 3.31 (s, 3H), 3.13 (s, 2H), 2.97 (m, 1H), 2.90 (s, 3H), 2.75–2.65 (m, 2H), 2.26 (brd, *J* = 12 Hz, 1H), 2.18 (dd, *J* = 4.8, 16 Hz, 1H), 1.89 (m, 1H), 1.81–1.65 (m, 4H), 1.51 (m, 1H), 1.20 (s, 3H), 1.17 (s, 9H), 1.14 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H); <sup>13</sup>C NMR (C<sub>6</sub>D<sub>6</sub>, 100 MHz) δ 171.6, 159.6, 140.8, 138.2, 136.30, 136.26, 134.4, 134.2, 131.8, 130.1, 129.3, 129.2, 128.0, 127.9, 114.0, 104.3, 100.5, 78.1, 77.2, 74.6, 71.4, 71.2, 69.7, 66.5, 54.7, 51.2, 48.0, 44.7, 43.6, 43.5, 42.4, 39.0, 38.2, 37.6, 33.2, 27.1, 23.9, 23.7, 21.1, 19.5, 16.8; IR (film): 3444, 2933, 1738, 1614, 1514, 1248 cm<sup>-1</sup>; HRMS (C<sub>50</sub>H<sub>69</sub>O<sub>9</sub>BrSi): calcd 943.3792 (*M* + Na<sup>+</sup>), found 943.3801.

**Compound 26.** To a solution of hydroxyacid **24** (74 mg, 0.12 mmol) in DCM (2.5 mL) was added freshly distilled 2,6-lutidine (62 mg, 0.58 mmol) at −10 °C, followed by dropwise addition of freshly distilled TESOTf (67 mg, 0.25 mmol). The resulting solution was stirred at the same temperature for 20 min, before poured into pH 7.0 buffer. The mixture was extracted with ethyl acetate five times and the combined organic fractions were dried over Na<sub>2</sub>SO<sub>4</sub>. The TES ether–acid **22** was purified via quick silica gel flash column chromatography (10%, 20% then 30% ethyl acetate/petroleum ether) to give a colorless foam (73 mg, 79%). (Significant decomposition has been observed when slower chromatography was applied.)

To a solution of TES ether–acid **22** (17.0 mg, 0.0225 mmol) in dry toluene (0.5 mL) was added Et<sub>3</sub>N (4.8 mg, 0.047 mmol) at rt under N<sub>2</sub>, followed by dropwise addition of freshly distilled 2,4,6-trichlorobenzoyl chloride (5.6 mg, 0.024 mmol) at rt. The resulting solution was stirred at rt for 1 h, before a solution of alcohol **23** (10.1 mg, 0.0225 mmol) and DMAP (6.9 mg, 0.056 mmol) in toluene (0.75 mL) was added. The resulting mixture was stirred at rt for another 1 h, before poured into pH 7.0 buffer. The mixture was extracted with ethyl acetate four times and the combined organic fractions were dried over Na<sub>2</sub>SO<sub>4</sub>. The ester **26** was purified via silica gel flash column chromatography (10%, then 20% ethyl acetate/petroleum ether) to give a colorless foam (25 mg, 92%). *R*<sub>f</sub>: 0.35 (ethyl acetate:petroleum ether, 1:4 v/v); [α]<sub>D</sub><sup>20</sup> (deg cm<sup>3</sup> g<sup>-1</sup> dm<sup>-1</sup>): +62.6 (*c* 0.11 g cm<sup>-3</sup> in DCM); <sup>1</sup>H NMR (C<sub>6</sub>D<sub>6</sub>, 500

MHz)  $\delta$  7.41 (d,  $J$  = 8.5 Hz, 2H), 7.24 (d,  $J$  = 8.5 Hz, 2H), 6.85 (d,  $J$  = 8.5 Hz, 2H), 6.79 (d,  $J$  = 8.5 Hz, 2H), 6.07 (dd,  $J$  = 5.0, 15.5 Hz, 1H), 5.93 (s, 1H), 5.79 (dd,  $J$  = 1.5, 15.5 Hz, 1H), 5.48 (ddd,  $J$  = 2.0, 4.0, 10.5 Hz, 1H), 4.60 (m, 1H), 4.53 (d,  $J$  = 10.5, 1 H), 4.47 (d,  $J$  = 11.5 Hz, 1H), 4.42 (d,  $J$  = 10.5 Hz, 1H), 4.32 (brd,  $J$  = 15.5 Hz, 1H), 4.27 (d,  $J$  = 11.5 Hz, 1H), 3.97 (m, 1H), 3.88–3.83 (2H), 3.79 (m, 1H), 3.67 (m, 1H), 3.45 (s, 3H), 3.33 (s, 3H), 3.30 (s, 3H), 3.28 (s, 3H), 3.27 (s, 3H), 2.70 (br s, 1H), 2.69 (d,  $J$  = 2.0 Hz, 1H), 2.38–2.25 (4H), 2.07–1.89 (6H), 2.01 (s, 1H), 1.84 (dd,  $J$  = 5.0, 16 Hz, 1H), 1.80 (m, 1H), 1.65 (m, 1H), 1.57 (dd,  $J$  = 9.5, 19.5 Hz, 2H), 1.29 (s, 3H), 1.22 (s, 3H), 1.21 (s, 6H), 1.18 (d,  $J$  = 6.0 Hz, 3H), 1.07 (t,  $J$  = 6.5 Hz, 9H), 1.00 (3, 9H), 0.72 (m, 6H), 0.17 (s, 3H), 0.12 (s, 3H);  $^{13}\text{C}$  NMR ( $\text{C}_6\text{D}_6$ , 125 MHz)  $\delta$  170.9, 166.7, 159.8, 159.6, 157.7, 153.9, 136.8, 131.7, 130.5, 130.1, 129.3, 128.7, 128.3, 128.1, 127.9, 114.9, 114.1, 114.03, 113.96, 104.5, 89.4, 85.8, 78.5, 77.5, 75.6, 75.1, 73.6, 73.4, 72.1, 71.5, 70.5, 68.7, 67.8, 66.2, 54.74, 54.70, 52.0, 50.6, 48.3, 44.9, 44.3, 43.7, 43.6, 39.5, 36.4, 34.4, 33.8, 33.5, 29.8, 26.01, 25.96, 24.5, 21.2, 18.6, 18.2, 17.0, 7.3, 5.7, -4.6, -4.7; IR (film): 2927, 2240, 1717, 1651, 1614, 1514, 1463, 1377, 1250, 1075  $\text{cm}^{-1}$ ; HRMS ( $\text{C}_{66}\text{H}_{100}\text{O}_{15}\text{Si}_2$ ): calcd 1211.6499 ( $\text{M} + \text{Na}^+$ ), found 1211.6484.

**Compound 30.** To a mixture of  $\text{Pd}(\text{OAc})_2$  (4.4 mg, 0.02 mmol) and TDMPP [tris(2,6-dimethoxyphenyl)phosphine] (11.2 mg, 0.025 mmol) was added freshly distilled toluene (1 mL). The mixture was stirred at rt for 30 min, and the resulting red solution (0.02 mL, ca. 0.0004 mmol) was slowly added a solution of diyne **21** (3.2 mg, 0.0034 mmol) in freshly distilled toluene (1.6 mL) under  $\text{N}_2$ . The reaction was stirred at rt for 3 days, before it was filtered through a short plug of silica gel. The solvent was removed under vacuum and the macrocycle **30** was purified via silica gel flash column chromatography (20%, 30% then 40% ethyl acetate/petroleum ether) to give a white paste (1.8 mg, 56%).

The same reaction was also carried out with  $\text{Pd}(\text{OAc})_2$  (1.1 mg, 0.0048 mmol), TDMPP (1.6 mg, 0.0075 mmol), diyne **21** (45 mg, 0.048 mmol) in toluene (20 mL) to give macrocycle **30** (16.0 mg, 36% yield; 16.7 mg **21** was recover, 57% yield brsm).  $R_f$ : 0.35 (ethyl acetate:petroleum ether, 3:7 v/v);  $[\alpha]_{\text{D}}^{20}$  (deg  $\text{cm}^3 \text{g}^{-1} \text{dm}^{-1}$ ): -43.8 ( $c$  0.21  $\text{g cm}^{-3}$  in DCM);  $^1\text{H}$  NMR ( $\text{C}_6\text{D}_6$ , 500 MHz)  $\delta$  6.32 (s, 1H), 6.12 (dd,  $J$  = 3.5, 15.5 Hz, 1H), 5.89 (d,  $J$  = 15 Hz, 1H), 5.73 (s, 1H), 5.34 (d,  $J$  = 10.5 Hz, 1H), 4.67 (m, 1H), 4.36 (d,  $J$  = 13 Hz, 1H), 4.31 (m, 1H), 4.12 (d,  $J$  = 11 Hz, 1H), 4.03–4.00 (2H), 3.91 (m, 1H), 3.86 (m, 1H), 3.40 (s, 3H), 3.38 (t,  $J$  = 7.5 Hz, 1H), 3.26 (s, 3H), 3.21 (s, 3H), 3.16 (dd,  $J$  = 5.0, 14.5 Hz, 1H), 2.68 (dd,  $J$  = 3.0, 16 Hz, 1H), 2.62 (dd,  $J$  = 9.0, 16 Hz, 1H), 2.21 (dd,  $J$  = 8.0, 16 Hz, 1H), 2.00 (m, 1H), 1.92–1.84 (4H), 1.65–1.53 (3H), 1.46 (m, 1H), 1.36–1.29 (2H), 1.24 (s, 3H), 1.22 (s, 3H), 1.19 (d,  $J$  = 6.5 Hz, 3H), 1.10 (s, 3H), 1.09 (s, 3H), 1.07 (t,  $J$  = 8.0 Hz, 9H), 0.98 (s, 9H), 0.66 (m, 6H), 0.16 (s, 3H), 0.11 (s, 3H);  $^{13}\text{C}$  NMR ( $\text{C}_6\text{D}_6$ , 125 MHz)  $\delta$  172.3, 166.5, 157.7, 140.2, 134.9, 129.1, 128.2, 127.9, 125.1, 114.8, 103.5, 102.0, 83.9, 76.4, 75.1, 74.3, 70.0, 68.7, 67.4, 66.9, 65.9, 50.9, 50.6, 49.1, 46.5, 44.6, 43.2, 42.8, 40.6, 40.2, 37.2, 36.8, 36.4, 34.6, 30.2, 29.8, 29.6, 26.0, 20.6, 18.5, 18.3, 16.6, 7.35, 6.0, -4.68, -4.72; IR (film): 3442 (br), 2924, 2853, 1717, 1650, 1614, 1435, 1376, 1256, 1151, 1107  $\text{cm}^{-1}$ ; HRMS ( $\text{C}_{50}\text{H}_{84}\text{O}_{13}\text{Si}_2$ ): calcd 971.5348 ( $\text{M} + \text{Na}^+$ ), found 971.5341.

**Bryostatin 16.** To a solution of pivalate ester **35** (1.0 mg, 0.001 mmol) in THF (0.05 mL) was added TBAF (0.005 mL, 0.005 mmol, 1M) at 0 °C. The resulting solution was allowed to slowly warm to rt and stirred for 4 h. The reaction mixture was diluted with ethyl acetate and pH 7.0 buffer was added. The mixture was extracted with ethyl acetate five times and the combined organic fractions were dried over  $\text{Na}_2\text{SO}_4$ . The residue was purified by reverse phase HPLC (RP C-18 column,  $\text{CH}_3\text{CN}$  in  $\text{H}_2\text{O}$  from 65% to 95%) to give **1** as a white paste (0.4 mg, ca. 52%).  $R_f$ : 0.35 (ethyl acetate:petroleum ether, 4:1 v/v);  $[\alpha]_{\text{D}}^{20}$  (deg  $\text{cm}^3 \text{g}^{-1} \text{dm}^{-1}$ ): +81 ( $c$  0.04  $\text{g cm}^{-3}$  in MeOH); For NMR data, see the Supporting Information; IR (film): 3359 (br), 2958, 2917, 2849, 1722, 1702,

1605, 1614, 1433, 1375, 1259, 1154, 1099  $\text{cm}^{-1}$ ; HRMS ( $\text{C}_{42}\text{H}_{62}\text{O}_{14}$ ): calcd 913.4037 ( $\text{M} + \text{Na}^+$ ), found 913.4038.

**Compound 41.** To a mixture of  $\text{Au}(\text{PPh}_3)_3\text{Cl}$  (10.2 mg, 0.020 mmol) and  $\text{AgSbF}_6$  (7.0 mg, 0.020 mmol) was added dry DCM (0.5 mL) at rt under  $\text{N}_2$ . The resulting mixture was stirred in the dark for 15 min, and a purple precipitate was formed. The supernatant solution (0.015 mL, ca. 0.0006 mmol) was transferred to a mixture of compound **40** (2.9 mg, 0.0030 mmol) and  $\text{NaHCO}_3$  (2.4 mg, 0.03 mmol) in DCM/ $\text{CH}_3\text{CN}$ /2,2-dimethoxypropane, (10:1:2, 0.4 mL) at 0 °C under  $\text{N}_2$ . The resulting reaction mixture was stirred vigorously overnight, before it was poured into a mixture of saturated aqueous  $\text{NaHCO}_3$  and saturated aqueous  $\text{Na}_2\text{S}_2\text{O}_3$  (ca. 1:1), and then the mixture was extracted with ethyl acetate four times and the combined organic fractions were dried over  $\text{Na}_2\text{SO}_4$ . Dihydropyran **41** was purified via *quick silica gel* flash column chromatography (10%, then 20% ethyl acetate/petroleum ether) to give a colorless foam (2.4 mg, 83%):  $R_f$ : 0.3 (10% ethyl acetate in petroleum ether);  $[\alpha]_{\text{D}}^{20}$ : 42.5 ( $c$  0.17, DCM);  $^1\text{H}$  NMR ( $\text{C}_6\text{D}_6$ , 500 MHz):  $\delta$  6.13 (d,  $J$  = 15.5 Hz, 1H), 5.74 (s, 1H), 5.73 (dd,  $J$  = 4.5, 15.5 Hz, 1H), 5.67 (dd,  $J$  = 5.0, 12 Hz, 1H), 5.61 (s, 1H), 5.46 (dd,  $J$  = 4.5, 11 Hz, 1H), 5.37 (s, 1H), 4.63 (m, 1H), 4.37 (d,  $J$  = 13 Hz, 1H), 4.02–3.91 (m, 4H), 3.77 (t,  $J$  = 12 Hz, 1H), 3.43 (s, 3H), 3.41 (s, 3H), 3.11 (s, 3H), 2.68 (dd,  $J$  = 5.0, 15 Hz, 1H), 2.42–2.34 (m, 2H), 2.18 (dd,  $J$  = 8.5, 16 Hz, 1H), 2.05–1.84 (m, 5H), 1.78 (m, 1H), 1.75 (s, 3H), 1.65–1.45 (5H) 1.30 (s, 3H), 1.24 (s, 3H), 1.12 (s, 3H), 1.09 (s, 3H), 1.05 (d,  $J$  = 7.0 Hz, 3H), 1.03 (s, 9H), 0.97 (t,  $J$  = 8.0 Hz, 9H), 0.57 (m, 6H), 0.23 (s, 3H), 0.13 (s, 3H);  $^{13}\text{C}$  NMR ( $\text{C}_6\text{D}_6$ , 125 MHz)  $\delta$  170.0, 169.8, 169.3, 167.3, 158.2, 150.5, 136.2, 129.1, 128.5, 127.8, 125.0, 114.7, 108.9, 103.2, 100.9, 77.0, 73.8, 73.7, 73.4, 72.4, 68.1, 66.8, 64.7, 50.5, 50.4, 48.2, 44.8, 44.0, 42.7, 42.2, 41.0, 39.7, 37.0, 33.8, 33.7, 32.4, 30.2, 26.0, 25.0, 24.9, 20.72, 20.70, 18.3, 18.0, 17.9, 7.2, 6.0, -4.7; IR (film) 2953, 2929, 1734, 1608, 1614, 1435, 1375, 1245, 1150, 1102  $\text{cm}^{-1}$ ; HRMS ( $\text{C}_{52}\text{H}_{86}\text{O}_{14}\text{Si}_2$ ): calcd 1013.5454 ( $[\text{M} + \text{Na}]^+$ ), found 1013.5453.

**Compound 44.** UHP (37.6 mg, 0.4 mmol) was added to a solution of MTO (5.0 mg, 0.02 mmol), *N*-methylimidazole (8.2 mg, 0.1 mmol) in freshly distilled MeOH (2 mL) at rt. The resulting solution was stirred at rt for 5 min, during which the color of the reaction turned to yellow. A portion of the above solution (0.026 mL) was added to a solution of **41** (2.5 mg, 0.0026 mmol) in MeOH (0.2 mL) at 0 °C. The resulting reaction mixture was stirred at °C for 6 h (monitored by TLC) before it was quenched with saturate aqueous  $\text{NaHCO}_3$  and  $\text{Na}_2\text{S}_2\text{O}_3$ . The mixture was extracted with ethyl acetate four times and the combined organic fractions were dried over  $\text{Na}_2\text{SO}_4$ . The crude epoxide product was obtained after the solvent was removed under vacuum. To the above crude epoxide was added a solution of HOAc in MeOH (0.2 mL, obtained from 1 drop of HOAc in 1 mL MeOH) at 0 °C. The resulting solution was stirred at 0 °C for 3 h (monitored by TLC), before it was quenched with saturate aqueous  $\text{NaHCO}_3$ . The mixture was extracted with ethyl acetate four times and the combined organic fractions were dried over  $\text{Na}_2\text{SO}_4$ . Compound **44** was purified via silica gel flash column chromatography (10%, then 20% ethyl acetate/petroleum ether) to give a colorless foam (1.7 mg, 64%).

**A One-Pot Protocol.** UHP (19 mg, 0.2 mmol) was added to a solution of MTO (5.0 mg, 0.02 mmol), *N*-methylimidazole (8.2 mg, 0.1 mmol) in freshly distilled MeOH (1 mL) at rt. The resulting solution was stirred at rt for 5 min, during which the color of the reaction turned to yellow. A portion of the above solution (0.021 mL, 10 mol % MTO) was added to a solution of **41** (4.3 mg, 0.0044 mmol) in MeOH (0.3 mL) and DCM (0.2 mL) at 0 °C for 30 min, before another portion of the oxidant (0.022 mL) was added. The resulting reaction mixture was stirred at °C for 3 h (monitored by TLC) before it was cooled to -78 °C and  $\text{ZnCl}_2$  (0.020 mL, 1.0 M in ether) was added. The resulting solution was stirred at 4 °C for 4 h (monitored by TLC), before it was quenched with saturate aqueous  $\text{NaHCO}_3$  and  $\text{Na}_2\text{S}_2\text{O}_3$ . The mixture was extracted with ethyl acetate four times and the combined organic fractions were

dried over  $\text{Na}_2\text{SO}_4$ . Compound **44** was purified via silica gel flash column chromatography (10%, then 20% ethyl acetate/petroleum ether) to give a colorless foam (2.2 mg, 48%);  $R_f$ : 0.33 (15% ethyl acetate in petroleum ether);  $[\alpha]_D^{25}$ : 57.7 (*c* 0.17, DCM); For NMR data, see the Supporting Information; IR (film): 3400 (br), 2954, 2928, 2856, 1722, 1651, 1378, 1247, 1098  $\text{cm}^{-1}$ ; HRMS ( $\text{C}_{53}\text{H}_{90}\text{O}_{16}\text{Si}_2$ ): calcd 1061.5665 ( $[\text{M} + \text{Na}]^+$ ), found 1061.5640.

**Compound 47.** To a solution of alcohol **44** (1.0 mg, 0.001 mmol) in pyridine (0.15 mL) was added acetic anhydride (0.1 mL) at 0 °C, followed by DMAP (1.0 mg, 0.008 mmol). The resulting solution was stirred at rt for 4 h, before it was quenched with MeOH (0.1 mL), followed by pH 7.0 Buffer at 0 °C. The mixture was extracted with ethyl acetate four times and the combined organic fractions were dried over  $\text{Na}_2\text{SO}_4$ . The residue was purified by silica gel column chromatography (10%, then 20% ethyl acetate/petroleum ether) to give compound **46** (ca. 1.0 mg) as a colorless thick oil.

To a solution of the above acetate (**46**, ca. 1.0 mg) in  $\text{CH}_3\text{CN}$  (0.2 mL) was added aqueous HF (2 drops, conc. 48–53%) at 0 °C. The resulting solution was stirred at a warming ice-bath for 2.5 h, before solid  $\text{K}_2\text{HPO}_4$  and saturated aqueous  $\text{NaHCO}_3$  were added. The mixture was extracted with ethyl acetate four times and the combined organic fractions were dried over  $\text{Na}_2\text{SO}_4$ . The residue was purified by preparative TLC (60% ethyl acetate in petroleum ether) to give 20-*epi*-bryostatin 7 (**47**) as a white paste (0.5 mg, ca. 63% over two steps);  $R_f$ : 0.30 (60% ethyl acetate in petroleum

ether);  $[\alpha]_D^{25}$ : 27.6 (*c* 0.07, DCM); For NMR data, see the Supporting Information; IR (film): 3455, 3300(br), 2924, 2853, 1722, 1652, 1374, 1243, 1153, 1077  $\text{cm}^{-1}$ ; HRMS ( $\text{C}_{41}\text{H}_{60}\text{O}_{17}$ ): calcd 847.3728 ( $[\text{M} + \text{Na}]^+$ ), found 847.3741.

**Acknowledgment.** We acknowledge the National Institutes of Health (GM 13598) for their support of our programs. G.D. was a Stanford Graduate Fellow. We thank Dr. H. Yang for discussions and for help characterizing compound **35**, and we additionally thank him and Dr. C. S. Brindle for providing synthetic intermediates. Palladium and ruthenium salts were supplied by Johnson Matthey. We are grateful to Dr. J. Flygare and Genentech for performing the preliminary biological test of 20-*epi*-bryostatin 7. We also acknowledge Dr. S. R. Lynch for his help with two-dimensional nuclear magnetic resonance analysis. We also thank the Wender group's assistance with reverse-phase high-performance liquid chromatography.

**Supporting Information Available:** Experimental procedures and characterization data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JA105129P